197 related articles for article (PubMed ID: 23725184)
1. Intrapleural or intraperitoneal lobaplatin for treatment of patients with malignant pleural effusion or ascites.
Huang XE; Wei GL; Huo JG; Wang XN; Lu YY; Wu XY; Liu J; Xiang J; Feng JF
Asian Pac J Cancer Prev; 2013; 14(4):2611-4. PubMed ID: 23725184
[TBL] [Abstract][Full Text] [Related]
2. Intrapleural combination therapy with lobaplatin and erythromycin for non-small cell lung cancer-mediated malignant pleural effusion.
Xu L; Wang B; Gao M; Zhang Y; Qi Q; Li T; Li C; Wang A; Li Y
Thorac Cancer; 2018 Aug; 9(8):950-955. PubMed ID: 29917319
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
[TBL] [Abstract][Full Text] [Related]
4. Increase of ascites and pleural effusion misleading assessment of antitumor response to erlotinib in adenocarcinoma of the lung.
Tachihara M; Misa K; Uematsu M; Minemura H; Katsuura Y; Ishida T; Munakata M
J Clin Oncol; 2011 Aug; 29(23):e675-7. PubMed ID: 21690480
[No Abstract] [Full Text] [Related]
5. Better Clinical Efficiency of TILs for Malignant Pleural Effusion and Ascites than Cisplatin Through Intrapleural and Intraperitoneal Infusion.
Chu H; Du F; Gong Z; Lian P; Wang Z; Li P; Hu B; Chi C; Chen J
Anticancer Res; 2017 Aug; 37(8):4587-4591. PubMed ID: 28739756
[TBL] [Abstract][Full Text] [Related]
6. [A Meta-Analysis of Efficacy and Adverse Effects of Lobaplatin and Cisplatin in the Treatment of Malignant Pleural Effusion].
Min S; Zheng Q; Zhang B; Yan D; Wang R; Qu Z; Li L; Liu J; Zhou Q
Zhongguo Fei Ai Za Zhi; 2019 Feb; 22(2):90-98. PubMed ID: 30827325
[TBL] [Abstract][Full Text] [Related]
7. Effective Treatment for Malignant Pleural Effusion and Ascites with Combined Therapy of Bevacizumab and Cisplatin.
Jiang L; Li P; Gong Z; Hu B; Ma J; Wang J; Chu H; Zhang L; Sun P; Chen J
Anticancer Res; 2016 Mar; 36(3):1313-8. PubMed ID: 26977031
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of intraperitoneal or intrapleural administration of triamcinolone acetonide for the control of malignant ascites and pleural effusion (Kansai Clinical Oncology Group-G1102 study).
Ito K; Tsubamoto H; Inoue K; Miyoshi Y; Ito Y; Hori K
J Cancer Res Ther; 2017; 13(3):446-450. PubMed ID: 28862207
[TBL] [Abstract][Full Text] [Related]
9. A phase I feasibility and pharmacokinetic study of intrapleural paclitaxel in patients with malignant pleural effusions.
Perng RP; Wu MF; Lin SY; Chen YM; Lin JY; Whang-Peng J
Anticancer Drugs; 1997 Jul; 8(6):565-73. PubMed ID: 9300570
[TBL] [Abstract][Full Text] [Related]
10. Influence of lymphocytes in malignant pleural effusion on the therapeutic efficacy of intrapleural OK-432 in lung cancer patients.
Shimizu T; Takahashi N; Terakado M; Akusawa H; Tsujino I; Horie T
Intern Med; 2006; 45(11):715-20. PubMed ID: 16819251
[TBL] [Abstract][Full Text] [Related]
11. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial.
Rusch VW; Figlin R; Godwin D; Piantadosi S
J Clin Oncol; 1991 Feb; 9(2):313-9. PubMed ID: 1988578
[TBL] [Abstract][Full Text] [Related]
12. A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non-small-cell lung cancer.
Nie K; Zhang Z; You Y; Zhuang X; Zhang C; Ji Y
Thorac Cancer; 2020 Jan; 11(1):8-14. PubMed ID: 31726490
[TBL] [Abstract][Full Text] [Related]
13. [Comparison of intrapleural OK-432 and cisplatin for malignant pleural effusion in lung cancer patients].
Shimizu T; Takahashi N; Terakado M; Sato M; Sugane T; Kisohara A; Akusawa H; Tsujino I; Horie T
Gan To Kagaku Ryoho; 2005 Aug; 32(8):1139-43. PubMed ID: 16121916
[TBL] [Abstract][Full Text] [Related]
14. A clinical Comparison of Lobaplatin or Cisplatin with Mitomycine and Vincristine in Treating Patients with Cervical Squamous Carcinoma.
Li WP; Liu H; Chen L; Yao YQ; Zhao EF
Asian Pac J Cancer Prev; 2015; 16(11):4629-31. PubMed ID: 26107215
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of intrapleural paclitaxel injection for non-small-cell lung cancer patients with malignant pleural effusions.
Perng RP; Chen YM; Wu MF; Chou KC; Lin WC; Liu JM; Whang-Peng J
Respir Med; 1998 Mar; 92(3):473-9. PubMed ID: 9692108
[TBL] [Abstract][Full Text] [Related]
16. Effect of medical thoracoscopy-guided intrapleural docetaxel therapy to manage malignant pleural effusion in patients with non-small cell lung cancer: A pilot study.
Choi MG; Park S; Oh DK; Kim HR; Lee GD; Lee JC; Choi CM; Ji W
Thorac Cancer; 2019 Oct; 10(10):1885-1892. PubMed ID: 31389192
[TBL] [Abstract][Full Text] [Related]
17. Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer.
Tohda Y; Iwanaga T; Takada M; Yana T; Kawahara M; Negoro S; Okishio K; Kudoh S; Fukuoka M; Furuse K
Chemotherapy; 1999; 45(3):197-204. PubMed ID: 10224342
[TBL] [Abstract][Full Text] [Related]
18. Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial.
Seto T; Ushijima S; Yamamoto H; Ito K; Araki J; Inoue Y; Semba H; Ichinose Y;
Br J Cancer; 2006 Sep; 95(6):717-21. PubMed ID: 16940982
[TBL] [Abstract][Full Text] [Related]
19. Intrapleural administration of recombinant interleukin-2 in non-small cell lung cancer with neoplastic pleural effusion.
Masotti A; Fumagalli L; Morandini GC
Monaldi Arch Chest Dis; 1997 Jun; 52(3):225-8. PubMed ID: 9270246
[TBL] [Abstract][Full Text] [Related]
20. [Intrapleural DDP and systemic thiosulfate rescue in the treatment of malignant pleural effusion].
Hua X; Lu W; Duan G
Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):50-2. PubMed ID: 7656790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
